medigraphic.com
ISSN 1561-3070 (Digital)

2014, Número 3

<< Anterior Siguiente >>

Rev Cub Oftal 2014; 27 (3)


Intravítrea de bevacizumab en el edema macular secundario a oclusión venosa de rama retiniana

Chiang RC, Rúa MR, Llanes DS, Toledo GY, Lapido PS, Baldoquín RW

Idioma: Español
Referencias bibliográficas: 49
Paginas: 403-415
Archivo PDF: 192.13 Kb.


RESUMEN

Objetivo: evaluar los resultados del tratamiento de intravítrea de bevacizumab en el edema macular secundario a oclusión de rama venosa retiniana.
Métodos: estudio prospectivo, intervencional, no comparativo, en 18 pacientes con edema macular secundario a oclusión de rama venosa retiniana. El tratamiento fue de inyección intravítrea de bevacizumab (hasta 3 dosis) seguido de grid macular si era necesario. La evaluación inicial fue a los 3 meses de la oclusión y se siguieron a los pacientes por 12 meses. Se evaluó la agudeza visual mejor corregida, el grosor macular y la ocurrencia de complicaciones.
Resultados: los pacientes fueron 7 hombres (38,89 %) y 11 mujeres (61,11 %). El promedio de edad fue de 63,1 (44-80). Durante el tratamiento, hubo 7 pacientes con 1 dosis (38,89 %), 6 con 2 dosis (33,33 %) y 5 con 3 dosis (27,77 %) más grid macular. Al inicio, el promedio de la mejor agudeza visual con corrección fue de 0,24 (0,05-0,5) y del grosor macular de 546,2 (283-1 020) µ. A los 12 meses la mejor agudeza visual con corrección promedio mejoró a 0,65 (0,1-1,0) y el grosor macular a 181,05 (112-312) μ. No hubo complicaciones asociadas con el proceder.
Conclusión: la inyección intravítrea de bevacizumab constituye un tratamiento eficaz en el edema macular secundario a oclusión de rama venosa retiniana.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Scott IV. Macular Edema Associated With Retinal Vein Occlusion. Retina Today. 2010: 54-5.

  2. Rogers SL, McIntosh RL. Natural history of branch retinal vein occlusion: Evidence-based systematic review. Ophthalmology. 2010;117(6):1 094-101.

  3. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol. 2011;5:1043-9.

  4. Shak GK. Treatment of Retinal Vein Occlusion. Individualized therapy is crucial to good patient outcomes. Retina Today. 2012:70-1.

  5. Rogers S, Mepid RL. The Prevalence of Retinal Vein Occlusion Pooled Data from Population Studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313-9

  6. Haller JA. Evaluating and Integrating New Evidence in the Treatment of RVO. Retina Today. 2010 [citado 23 de octubre de 2012];(Supp.):[aprox 31 p.]. Disponible en: http://www.bmctoday.net/retinatoday/2010/10/ supplement/article.asp?f=evaluating-and-integrating-new-evidence-in-thetreatment- of-rvo

  7. Brown DM. New Directions in RVO Treatment. Retina Today. 2010(Supp.):3-7.

  8. Ho AC, Ip M. An Evidence-based Approach for RVO: Corticosteroids, implants and anti- VEGF therapies. Retina Today. 2011:3-6.

  9. Schutze C, Schmidt-Erfurt U. Imaging for BRVO and CRVO. Retina Today. 2011:63-8.

  10. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis and treatment modalities. Current Eye Research. 2008;33(2):111-31.

  11. Hariprasad SM. Combination Therapy for RVO. Retina Today. 2010:67-76.

  12. Boyer DS. The pathophysiology of macular edema. Retina Today. 2011 [citado: 23 de octubre de 2012];(Supp.):[aprox 8 p.]. Disponible en: http://www.bmctoday.net/retinatoday/2011/09/supplement/article.asp?f=thepatho physiology-of-macular-edema

  13. Noma H, Funatsu H, Mimura T, Tatsugawa M, Shimada K, Eguchi S. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina. 2012;32(1):86-91.

  14. Cousins SW, Boyer DS. New and emerging treatment paradigms for macular edema in retinal vein occlusions and diabetic retinopathy. Retina Today. 2010(Supp):1-6.

  15. Holekamp NM, Ip MS. Point/Counterpoint Early vs Late Pharmacologic Therapy for RVO. Retina Today. 2010:68-70.

  16. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained- release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139-46.

  17. Scott IV, Vanveldhuisen PC. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: standard care versus corticosteroid for retinal vein occlusion. Study Report 10. Ophthalmology. 2011;118(2):345-52.

  18. Shahsuvaryan M. Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. Int J ophthalmol. 2012;5(6):759-70.

  19. Haller JA, Bandello F. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema du to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-46.

  20. Haller JA, Bandello F. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion, twelve- month study results. Ophthalmology. 2011;118(12):2453-60.

  21. Campochiaro PA, Heier JS. Ranibizumab for macular edema following Branch retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-12.

  22. Brown DM. Clinical implications of the Bravo and Cruise Trials. Retina Today. 2010:38-40.

  23. Kitchens J. Baseline predictors of the number of Ranibizumab retreatment injections in the Bravo study during months 6-11. Chicago: Poster presented at: American Academy of Ophthalmology Annual Meeting; October 16-19, 2010.

  24. Shapiro A, Boyer D, Nguyen QD. One year after aflibercept: where are we with therapeutic approaches for retinal vascular diseases? Retina Today. 2012:24-6.

  25. Fung A. Influence of baseline characteristics and dodsing on outcomes of antivegf therapy for retinal vein occlusions. Retina Today. 2011:58-60.

  26. Campochiaro PA. Anti-VEGF treatment for RVO: Clinical experience. Retina Today. 2011:58-60.

  27. Bandello F. Research drives treatment options for macular edema secondary to RVO. Ocular Surgery News. 2012 [citado 10 de octubre de 2012]. Disponible en: http://www.healio.com

  28. Blumenkranz M, Whitcup SM. Implant a First for ME after RVO. Benefits possible from Drug Delivery, effect on inflammation. Ophthalmology Times. 2009;34(14):50-4.

  29. Pieramaci DA review of the data regarding clinically available therapies and those on the horizon. Retina Today. 2010:1-6.

  30. Gallemare RP, Wallsh J. Management of retinal vein occlusion: what the clinical trials tell us. Retina Today. 2013:64-67.

  31. Figueroa MS, Noval S. Revisión actualizada de las terapias antiangiogénicas. Stud Ophthalmol. 2006;24(3):185-9.

  32. Figueroa MS, Contreras I. Results of Bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol. 2010;94(8):1052-6.

  33. Fish GE. Intravitreous Bevacizumab in the treatment of macular edema from Branch retinal vein occlusion ad hemisphere retinal vein occlusion. Trans Am Ophthalmol Soc. 2008;106:276-300.

  34. Ogino K, Tsujikawa A, Murakami T, Muraoka Y, Kurashige Y, Yoshimura N. Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. Clin Ophthalmol. 2011;5:1031-6.

  35. Salinas A, Zarranz J, Caire JM, Sádaba LM, Barrio J, García A. Intravitreal Bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2010;21(4):434-9.

  36. Shukla D, Behera UC, Chakraborty S, Mahalakshmi R, Prasad NM. Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection. Ophthalmic Surg Lasers Imaging. 2009;40(2):115-9.

  37. Benson WB. A Randomized Trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Evidence-Based Ophthalmol. 2010;11(1):22-3.

  38. Luttrull JK. Laser for Bravo: history and current practice. Retina Today. 2011(Supp.):17-9.

  39. Kiss S. Moving beyond laser in treatment of DME, Bravo. Retina Today. 2012:48-50.

  40. Badala F. The treatment of branch retinal vein occlusion with Bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-8.

  41. Wu W, Arébalo J, Berrocal MH, Rodríguez FJ, Costa R, Cardillo J. Comparison of two doses of intravitreal Bevacizumab (avastin) for treatment of macular edema secondary to Branch Retinal Vein Occlusion: Results from the Pan-American Collaborative Retie Study Group at 6 months of follow-up. Retina. 2008;28(2):212-9.

  42. Abegg M, Tappeiner C, Barthelmes D, Wolf S, Fleischhaner J. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmology. 2008;8:1-6.

  43. Gesine BJ, Martin L, Faik G, FockeZ, Karl UB, Szurman P. One year results after intravitreal Bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):27-33.

  44. Wong I, Koo S. Effect of intravitreal Bevacizumab (IVB) in treating macular edema secondary to branch retinal vein occlusion. Retina. 2010;30(4):710-1.

  45. Hu K, Horgan SE. Intravitreal Bevacizumab for macular oedema secondary to branch retinal vein occlusion: more data required. Eye. 2010;24(1):194-5.

  46. Hung KH, Lee SM. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(1):85-90.

  47. Chuang LH, Yeung L. Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion. J Ocul Pharmacol Ther. 2010;26(4):325-8.

  48. Wehrli S. A lack of delayed intraocular pressure elevation in patients with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32(7):1 295-301.

  49. Shima C. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86(4):372-6.




2020     |     www.medigraphic.com